Serial #79349914
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79349914 Trademark

Serial Number: 79349914 • Registration: 7369446

Serial #79349914 is a trademark filed by HANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD on July 15, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

HANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD (6 trademarks)

Room 116, 1st Floor, Building 2,

Entity Type: 03

Metis Therapeutics Inc. (4 trademarks)

101 Cambridgepark Drive, 3rd Floor

Entity Type: 03

Metis TechBio Co., Ltd.

Room 201, 2nd Floor, Building 13,

Entity Type: 98

Trademark Details

Filing Date

July 15, 2022

Registration Date

April 30, 2024

Published for Opposition

February 13, 2024

Goods & Services

Medicines for human purposes, namely, for use for central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney and gastrointestinal diseases; Pharmaceutical preparations, namely, for use for central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Chemico-pharmaceutical preparations, namely, for use for central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Capsules being medicines, namely, capsules for the treatment of central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney related diseases, gastrointestinal diseases; Sedatives; Vaccines; Drugs for medical purposes, namely, central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Medicines in tablet form, namely, medicinal preparations for the mouth to be applied in the form of tablets; Injectable medicinal solutions, namely, powder for injection, parenteral solutions, solutions for injection, intravenous injections, suspensions for injection, sterile powders for injection, intravenous injections, emulsion for injection, emulsion injections, powder injections, and concentrated solutions for injection, all for the treatment of central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney and gastrointestinal diseases; Pain relief medication; Immunostimulants; Pharmaceuticals for the treatment of cancer; Pharmaceuticals for the treatment of infectious diseases; Pharmaceuticals for the treatment of viral diseases; Medicinal preparations for the treatment of musculoskeletal disorders; Drugs and preparations for the treatment of gastrointestinal diseases; Medicinal preparations for skin diseases

Design of computer databases; Conversion of computer programs and data, other than physical conversion; Digitization of documents being scanning; Computer programming in medical care; Providing virtual computer systems through cloud computing; Pharmaceutical drug development; Drug evaluation in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Pharmaceutical research; Scientific research and development; Conducting early evaluation of new drug fields in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Computer hardware design; Research and development of new products for others; Providing computer software design for others; Electronic data storage; Conducting technical project studies in the nature of technical research in the field of pharmaceutical studies; Conversion of data or documents from physical to electronic media; Clinical trials, namely, scientific research in the nature of conducting clinical trials for others; Animal genetics research in the nature of studying the mechanism of action of compound combinations in animals; Computer programming

Filing History

CHANGE OF OWNER RECEIVED FROM IB
May 21, 2026 CHLD
NEW REPRESENTATIVE AT IB RECEIVED
Mar 19, 2026 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 7, 2024 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Oct 26, 2024 XXSS
GENERIC MADRID TRANSACTION CREATED
Oct 26, 2024 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 30, 2024 FICR
NEW REPRESENTATIVE AT IB RECEIVED
May 4, 2024 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 30, 2024 NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 30, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 30, 2024 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 11, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 21, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 21, 2024 OPNR
NOTIFICATION PROCESSED BY IB
Feb 14, 2024 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 13, 2024 NPUB
PUBLISHED FOR OPPOSITION
Feb 13, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 24, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 24, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 10, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 4, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 4, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 4, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 4, 2024 CNEA
CHANGE OF NAME/ADDRESS REC'D FROM IB
Dec 23, 2023 ADCH
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 12, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 12, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 12, 2023 TROA
CHANGE OF OWNER RECEIVED FROM IB
Dec 1, 2023 CHLD
ASSIGNED TO EXAMINER
Nov 19, 2023 DOCK
REFUSAL PROCESSED BY IB
Jul 22, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 23, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jun 23, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 18, 2023 RFCR
NON-FINAL ACTION WRITTEN
May 17, 2023 CNRT
ASSIGNED TO EXAMINER
May 2, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 23, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 19, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 16, 2022 REPR